Repligen (NASDAQ:RGEN) is scheduled to be issuing its quarterly earnings data before the market opens on Thursday, August 1st. Analysts expect the company to announce earnings of $0.25 per share for the quarter. Repligen has set its FY19 guidance at $0.84-0.90 EPS.Parties interested in registering for the company’s conference call can do so using this link.
Repligen (NASDAQ:RGEN) last announced its quarterly earnings results on Thursday, May 9th. The biotechnology company reported $0.28 earnings per share for the quarter, beating analysts’ consensus estimates of $0.26 by $0.02. Repligen had a net margin of 10.11% and a return on equity of 6.35%. The business had revenue of $60.63 million during the quarter, compared to analysts’ expectations of $55.09 million. During the same period last year, the business earned $0.17 earnings per share. The business’s revenue for the quarter was up 35.3% on a year-over-year basis. On average, analysts expect Repligen to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.
Shares of RGEN traded down $0.02 during trading on Tuesday, reaching $94.44. 228,731 shares of the company traded hands, compared to its average volume of 524,129. Repligen has a twelve month low of $45.00 and a twelve month high of $95.24. The firm has a market cap of $4.45 billion, a PE ratio of 129.37, a PEG ratio of 5.52 and a beta of 1.10. The business’s 50-day moving average is $84.31. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.84 and a current ratio of 2.18.
RGEN has been the subject of a number of recent analyst reports. BidaskClub cut shares of Woodward, Inc.Common Stock from a “strong-buy” rating to a “buy” rating in a research report on Saturday. HC Wainwright lifted their price target on shares of Cara Therapeutics from $28.00 to $31.00 and gave the company an “average” rating in a research report on Monday, July 22nd. Zacks Investment Research cut shares of Hallmark Financial Services from a “buy” rating to a “hold” rating in a research report on Thursday, July 18th. Finally, ValuEngine upgraded shares of United Overseas Bank from a “sell” rating to a “hold” rating in a research report on Monday, June 17th. Five equities research analysts have rated the stock with a buy rating and three have given a strong buy rating to the company’s stock. Repligen presently has a consensus rating of “Buy” and a consensus price target of $94.00.
In related news, Director Karen A. Dawes sold 1,295 shares of Repligen stock in a transaction that occurred on Monday, June 17th. The shares were sold at an average price of $77.35, for a total value of $100,168.25. Following the completion of the transaction, the director now owns 118,329 shares in the company, valued at $9,152,748.15. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Glenn L. Md Cooper sold 5,000 shares of Repligen stock in a transaction that occurred on Thursday, May 23rd. The shares were sold at an average price of $66.94, for a total transaction of $334,700.00. Following the completion of the transaction, the director now owns 35,975 shares of the company’s stock, valued at approximately $2,408,166.50. The disclosure for this sale can be found here. Insiders own 1.70% of the company’s stock.
Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process in North America, Europe, APAC, and internationally. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media.
Featured Story: What is Net Asset Value (NAV)?
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.